Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Results of the MARS study in renal cell carcinoma

2014 Genitourinary Cancers Symposium

30 Jan - 1 Feb 2014

Published: 31 Jan 2014

Views: 4089

Rating:

Save

Dr Vincent Launay-Vacher - Pitie-Salpetriere Hospital, Paris, France

Dr Vincent Launay-Vacher from Pitie-Salpetriere Hospital, Paris, France talks to ecancertv at ASCO GU congress 2014 about the results of the MARS study. This study is assessing the renovascular tolerance of anti-VEGF drugs in a clinical setting.

Dr Launay-Vacher also discusses the new Cancer & the Kidney International Network C-KIN

Related Videos

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

Myeloma treatment and prognosis

Dr Maitreyyee Bhattacharyya - Institute of Hematology and Transfusion medicine...

Myeloma treatment and prognosis ( Dr Maitreyyee Bhattacharyya - Institute of Hematology and Transfusion medicine, Medical College, Kolkata )

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of...

Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer ( Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG

Dr Roger Li - Moffitt Cancer Center, Tampa, USA

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy...

Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free...

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable...

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

More from ecancer